2018 Case Simulation: New Developments in Type 2 Diabetes Treatment to Decrease the Risk of Hypoglycemia

Due to the progressive nature of type 2 diabetes mellitus (T2DM), insulin is typically initiated when patients are unable to achieve and maintain glycated hemoglobin (HbA1c) target levels with lifestyle changes and addition of one or more antidiabetic drugs to the treatment regimen. However, the initiation and intensification of diabetes treatment with insulin is often delayed in many patients due to clinical inertia and fears of hypoglycemia. This educational activity will address the barriers to intensifying T2DM treatment with insulin, including clinical inertia and the risk of hypoglycemia, current treatment recommendations for glycemic control in T2DM, and efficacy and safety data for fixed-ratio insulin/GLP-1 RA combinations to achieve glycemic control and reduce hypoglycemic risk

This case-based, patient simulation technology will be utilized to provide learners with the opportunity to explore different decision paths and then immediately observe the consequences of their decisions—without risk. Learners will receive the benefit of engaging in deliberate practice in an environment that is safe, consistent, convenient and individualized to improve their management of patients with T2DM and risk of hypoglycemia.

2018 Case Simulation: New Developments in Type 2 Diabetes Treatment to Decrease the Risk of Hypoglycemia